Multi-analyte Biosensor for Emerging Cardiac Markers

月神创新提出创建一个敏感的，高度特异性的，多分析生物传感器用于心脏标记物的定量。研究人员和医生都需要这个系统来改进对胸痛患者的评估和分诊。新的即时诊断技术旨在快速定量常规标志物，包括心肌肌钙蛋白I、总肌酶激酶MB和肌红蛋白，试图满足这一需求，但只能识别斑块破裂事件的下游影响。最近的研究表明，新兴的标记物，如p -选择素和D-二聚体，可能是斑块破裂或不稳定的早期指标。该系统利用Luna的长周期光栅（LPG）光纤传感器和亲和膜技术，创建了一个高度复用、灵活的平台，用于直接、实时测量传统和新兴的心脏标志物。第一阶段的工作将展示具有肌酸激酶MB和p选择素的传感器平台。在第二阶段的项目中，更多的标记将被识别并集成到检测系统中。Luna之前已经演示了该技术用于快速，敏感和特异性检测血清中的蛋白质p24。提出的系统将使研究多种心脏标志物的意义，从而提高对心肌梗死的理解。提议的商业应用：提议的多分析物生物传感器系统在心肌梗死的研究和分类中有直接的应用。测量多种心脏标志物的能力将提高研究人员和医生对导致斑块破裂和下游效应的机制的理解。该系统一经建立就可作为即时诊断领域，如败血症的检测。其他医疗应用包括蛋白质组学和药物开发市场的高通量筛选。第一阶段项目旨在展示传感器性能的正交确认，从而建立客户对这种新型传感技术的信心。

Luna Innovations proposes to create a sensitive, highly specific, multi- analyte biosensor for quantification of cardiac markers. This system is needed by both researchers and physicians to improve evaluation and triage of patients reporting to emergency departments with chest pain. New point-of-care diagnostic technologies designed for rapid quantification of conventional markers including, cardiac troponin I, total creatinase kinase MB, and myoglobin attempt to address this need, but only identify downstream effects of a plaque rupture event. Recent studies have suggested emerging markers, such as P-selectin and D- dimer, may be early indicators of plaque rupture or instability. The proposed system utilizes Luna's long period grating (LPG) optical fiber sensor and affinity film technology to create a highly multiplexed, flexible platform for direct, real-time measurement of conventional and emerging cardiac markers. Phase I work will demonstrate the sensor platform with creatine kinase MB and P-selectin. Additional markers will be identified and integrated into the detection system during the Phase II program. Luna has prreviously demonstrated the proposed technology for rapid, sensitive, and specific detection of a protein, p24, in serum. The proposed system will enable studies into the significance of multiple cardiac markers leading to an improved understanding of myocardial infarction. PROPOSED COMMERCIAL APPLICATIONS: The proposed multi-analyte biosensor system has immediate application in research and triage of myocardial infarction. The ability to measure multiple cardiac markers will improve researchers and physicians understanding of the mechanisms leading up to plaque rupture and downstream effects. Upon establishing the system as a point-of-care diagnostic areas, such as detection of sepsis. Additional medical applications include high throughput screening in proteomic and pharmaceutical development markets. The Phase I program has been designed to demonstrate orthogonal confirmation of sensor performance, thus building customer confidence in this novel sensing technology.